HGH and IGF-1: Understanding the Downstream Axis

The GH/IGF-1 Axis: An Overview

The growth hormone / insulin-like growth factor-1 (GH/IGF-1) axis is one of the most consequential endocrine systems in mammalian biology — governing linear growth in development, anabolic metabolism throughout adulthood, and tissue homeostasis across multiple organ systems. Its central architecture is a classic hormonal relay: the hypothalamus secretes GHRH (and somatostatin as the inhibitory counter-signal), the pituitary responds with pulsatile GH secretion, and the liver responds to GH by producing IGF-1, which feeds back to suppress both GHRH and GH at the hypothalamic and pituitary levels respectively.

This apparently simple three-level cascade conceals substantial complexity: IGF-1 does not circulate freely but is bound to a family of six IGF binding proteins (IGFBPs 1–6) that regulate its bioavailability and tissue delivery; there is a substantial local (autocrine/paracrine) IGF-1 system in muscle, bone, and other tissues that operates independently of hepatic IGF-1; and IGF-1 shares significant structural and receptor homology with insulin, creating metabolic cross-signalling that must be understood to interpret HGH research correctly.

IGF-1 Molecular Weight

7,647 Da (70 amino acids)

Primary Production Site

Hepatocytes (systemic IGF-1); multiple tissues (local)

Plasma Half-life (free)

~10–15 minutes

Plasma Half-life (IGFBP-3 complex)

~12–16 hours

Primary Receptor

IGF-1R (receptor tyrosine kinase)

Key Downstream Pathway

PI3K → AKT → mTORC1 → p70S6K / 4E-BP1

Step 1: How HGH Stimulates IGF-1 Production

When GH is secreted from the pituitary (or administered exogenously), it binds GH receptors (GHR) on hepatocytes — the primary IGF-1–producing cells in the body. GHR is a single-pass transmembrane receptor that dimerises upon GH binding, activating the receptor-associated Janus kinase 2 (JAK2). Activated JAK2 phosphorylates STAT5b — a transcription factor that, once phosphorylated, dimerises and translocates to the nucleus where it binds the IGF1 gene promoter and drives IGF-1 transcription and translation.

STAT5b is the critical transcriptional mediator of GH-induced hepatic IGF-1 production. Humans and mice with loss-of-function STAT5b mutations have severely reduced IGF-1 levels despite normal or elevated GH — definitively establishing STAT5b as the obligate signalling intermediate. STAT5b also drives expression of the acid-labile subunit (ALS) — a key component of the ternary IGF-1 transport complex — and several IGFBP genes, demonstrating that GH coordinately regulates the entire IGF-1 distribution system at the transcriptional level.

Step 2: IGF Binding Proteins — The Regulatory Buffer System

Over 99% of circulating IGF-1 is bound to one of six IGF binding proteins (IGFBP-1 through IGFBP-6). These are not passive carriers — they are active regulatory proteins that control the bioavailability, half-life, tissue distribution, and receptor access of IGF-1. Understanding IGFBP biology is essential for interpreting serum IGF-1 measurements and for understanding the actual biological activity of the IGF-1 axis.

IGFBPRegulationPrimary FunctionResearch SignificanceIGFBP-1↑ by insulin deficiency, fasting; ↓ by insulinShort-term IGF-1 bioavailability modulator; inhibitory at high levelsAcute nutritional/insulin state marker; elevated in T1DM and fastingIGFBP-2↑ in GH deficiency, fasting; CNS expressionInhibitory binding; brain-specific IGF regulationElevated in GH deficiency; potential tumour marker in some cancersIGFBP-3↑ by GH; major carrier protein (forms ternary complex)Primary circulating IGF-1 carrier; extends half-life to 12–16 hoursBest single serum marker of GH/IGF-1 axis status alongside IGF-1IGFBP-4Regulated by PAPP-A protease cleavageInhibitory; PAPP-A cleavage at injury sites releases IGF-1 locallyTissue repair research — PAPP-A/IGFBP-4 axis governs local IGF-1 releaseIGFBP-5Regulated by growth factors; bone-enrichedCan be stimulatory or inhibitory depending on cell surface bindingBone biology; muscle research — complex context-dependent effectsIGFBP-6IGF-2 preferringPrimary IGF-2 binding protein; inhibitory for IGF-2–driven signallingFetal growth; muscle differentiation; some cancer biology

Step 3: The Ternary Complex — The 12-Hour Half-Life System

The dominant circulating form of IGF-1 is the ternary complex — a 150-kDa assembly of IGF-1, IGFBP-3 (or IGFBP-5), and acid-labile subunit (ALS). This complex is too large for glomerular filtration (above the 50-kDa renal filtration threshold) and cannot cross capillary endothelium, confining it to the vascular space. The ternary complex extends IGF-1's effective circulating half-life from ~10–15 minutes (for free IGF-1) to approximately 12–16 hours — creating a stable reservoir of GH-stimulated IGF-1 that buffers against moment-to-moment fluctuations in GH secretion.

This buffering function is why IGF-1 is such a reliable biomarker of integrated GH axis activity: it reflects cumulative GH exposure over the preceding 12–24 hours rather than the current GH level. A single blood sample for IGF-1 captured at any time of day provides a reliable assessment of axis activity, regardless of the pulsatile GH fluctuations occurring throughout the day. This is one of the most practically important properties of the IGF-1 measurement in GH research.

Step 4: IGF-1 Receptor Signalling

IGF-1 Signalling Cascade — Anabolic and Anti-Apoptotic Pathways

IGF-1 binds IGF-1R

→

IGF-1R autophosphorylation

→

IRS-1/2 recruitment

→

PI3K activation

→

AKT phosphorylation

Anabolic Branch

AKT → mTORC1 → p70S6K + 4E-BP1 → Protein synthesis ↑

Anti-Catabolic Branch

AKT → FOXO phosphorylation → FOXO nuclear exclusion → Atrogin-1/MuRF-1 ↓ → Protein degradation ↓

Proliferative Branch

IRS-1 → RAS → RAF → MEK → ERK → Cell proliferation + differentiation

Systemic vs Local IGF-1: A Critical Research Distinction

One of the most important and frequently misunderstood aspects of IGF-1 biology is the distinction between systemic (endocrine) IGF-1 — produced by the liver in response to GH and distributed via the circulation — and local (autocrine/paracrine) IGF-1 — produced by muscle, bone, brain, and other tissues in response to local stimuli including mechanical loading, local GH signalling, and growth factor activation.

Liver-specific IGF-1 knockout mice (LID mice) — which lack hepatic IGF-1 production and have serum IGF-1 reduced by 75% — grow normally and maintain normal muscle mass, bone density, and organ weights. This landmark finding by Yakar et al. (1999) demonstrated that systemic circulating IGF-1 is not required for normal tissue growth, and that local tissue-produced IGF-1 is sufficient to maintain growth and anabolism in most tissues. What circulating IGF-1 primarily does is regulate glucose metabolism — LID mice are hyperinsulinaemic and insulin-resistant, establishing circulating IGF-1's critical role in glucose homeostasis independent of its growth-promoting effects.

The practical implication for HGH research: measuring serum IGF-1 provides information about systemic GH axis activity and glucose metabolic regulation, but does not fully capture the anabolic effects of local tissue IGF-1 production that are stimulated by GH at the tissue level independently of hepatic IGF-1. Research endpoints focused on muscle protein synthesis, bone formation, or local tissue repair are driven by both systemic and local IGF-1, and serum IGF-1 alone does not capture the complete picture.

The IGF-1 / Insulin Cross-Signalling Problem

IGF-1 and insulin share approximately 70% structural homology and bind each other's receptors with reduced but significant affinity — IGF-1 binds the insulin receptor at approximately 1% of insulin's affinity, and insulin binds IGF-1R at similar cross-affinity. At supraphysiological IGF-1 levels produced by high-dose HGH, this cross-receptor activation becomes biologically significant: IGF-1 acting on insulin receptors produces insulin-like glucose-lowering effects that can cause hypoglycaemia, particularly in fasted states or after intense exercise. Conversely, at the high IGF-1 concentrations that directly suppress GH through feedback, IGF-1's mild insulin-like glucose lowering is counterbalanced by GH's strong insulin-antagonising effect on skeletal muscle — producing a complex net metabolic outcome that must be monitored carefully in HGH research protocols.

Feedback Regulation: Closing the Loop

IGF-1 completes the GH/IGF-1 axis by providing negative feedback at two levels. At the hypothalamus, circulating IGF-1 stimulates somatostatin-producing neurons in the periventricular nucleus — increasing somatostatin tone and reducing the frequency and amplitude of GHRH pulses. At the pituitary, IGF-1 acts directly on somatotroph cells to reduce GHRH receptor expression and inhibit GH gene transcription via STAT5b competition. This dual feedback mechanism is why exogenous HGH administration suppresses endogenous GH production — the elevated circulating IGF-1 produced by exogenous GH triggers feedback suppression of the pituitary, which reduces its endogenous GH output to near zero. Recovery of endogenous GH secretion after cessation of exogenous HGH requires normalisation of circulating IGF-1 and recovery of GHRH receptor sensitivity — a process that can take weeks to months depending on the duration and dose of prior treatment.

Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. HGH (somatropin) is a Schedule III controlled substance in the United States. All information pertains to published scientific research literature. This content does not constitute medical advice. Researchers must comply with all applicable laws and institutional regulations.

References

1. Jones JI, Clemmons DR. "Insulin-like growth factors and their binding proteins: biological actions." _Endocr Rev_. 1995;16(1):3–34.
2. Yakar S, et al. "Normal growth and development in the absence of hepatic insulin-like growth factor I." _Proc Natl Acad Sci USA_. 1999;96(13):7324–7329.
3. Waxman DJ, O'Connor C. "Growth hormone regulation of sex-dependent liver gene expression." _Mol Endocrinol_. 2006;20(11):2613–2629.
4. Clemmons DR. "Metabolic actions of IGF-1 in normal physiology and diabetes." _Endocrinol Metab Clin North Am_. 2012;41(2):425–443.
5. Baxter RC. "IGF binding proteins in cancer: mechanistic and clinical insights." _Nat Rev Cancer_. 2014;14(5):329–341.
6. LeRoith D, et al. "The role of the endocrine IGF-I system in brain growth." _Trends Endocrinol Metab_. 2001;12(2):67–72.